Related Experiment Videos
Low dose pulse methotrexate therapy in rheumatoid arthritis
The Journal of Rheumatology
|July 1, 1980
Summary
Low dose pulse methotrexate (MTX) effectively treated rheumatoid arthritis in two-thirds of patients, showing significant joint improvement. While some discontinued due to side effects, MTX offers a promising alternative to harsher immunosuppressants.
Area of Science:
- Rheumatology
- Immunosuppressive Therapy
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation.
- Current treatments for RA include disease-modifying antirheumatic drugs (DMARDs) and biologics, which can have significant side effects.
- Methotrexate (MTX) is a widely used immunosuppressive agent, but its efficacy and safety in low-dose pulse regimens for RA require further investigation.
Purpose of the Study:
- To evaluate the therapeutic efficacy and safety of low-dose pulse methotrexate (MTX) in patients with definite or classical rheumatoid arthritis.
- To assess clinical and laboratory parameters indicative of treatment response.
- To identify adverse events and reasons for treatment discontinuation.
Main Methods:
- A cohort of thirty-two patients with definite or classical rheumatoid arthritis received low-dose pulse methotrexate (MTX).
- Therapeutic response was assessed through statistically significant joint changes and global response assessments.
- Sedimentation rates were monitored, and liver enzyme levels were evaluated.
- Liver biopsies were performed in patients with abnormal liver enzymes.
Main Results:
- A therapeutic response was observed in two-thirds of the patients, evidenced by significant joint improvements and enhanced global assessments.
- Over half of the responders showed a decrease in their sedimentation rate.
- Eight patients discontinued MTX due to lack of efficacy, and two due to gastrointestinal distress.
- One patient experienced a fatal outcome from neoplasm.
- Five liver biopsies in patients with elevated liver enzymes revealed no methotrexate-related histological changes.
Conclusions:
- Low-dose pulse methotrexate (MTX) demonstrates potential as an effective treatment for rheumatoid arthritis.
- MTX may represent a viable alternative to other, more toxic immunosuppressive therapies.
- Further research and evaluation of MTX in RA treatment are warranted.